Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Acesion Pharma has named Anders Holst its chief medical officer. Holst was senior international medical director at Novo Nordisk. Acesion has also recruited Birgitte Vestbjerg to take on the role of director of clinical operations. Vestbjerg was most recently director of clinical operations at MC2 Therapeutics.
Gadi Saarony has joined Advarra as the consulting company’s CEO. Saarony comes to Advarra from PAREXEL, where he served as executive vice president and chief CRS officer.
Ed Ikeguchi, who previously served as chief medical officer and president of AiCure, has been named CEO of the company.
ANI Pharmaceuticals has named Patrick D. Walsh interim president and CEO to fill the gap left by the retiring CEO, Arthur Przybyl. Walsh has served on ANI’s board of directors since 2018 and has extensive pharmaceutical industry experience.
Antibe Therapeutics appointed Joseph Stauffer to the role of chief medical officer. Stauffer previously served as chief medical officer of Inheris Biopharma.
Joe Miller has joined Aurinia Pharmaceuticals as its chief financial officer. Miller was previously the chief financial officer at Cerecor.
Cardiff Oncology (Trovagene)
Cardiff Oncology, which recently changed its name from Trovagene, has appointed Mark Erlander to lead the company as its CEO. Erlander had been Cardiff’s chief scientific officer since 2013.
Codexis has hired Stefan Lutz to the role of senior vice president of research. Most recently, Lutz was professor and chair of the chemistry department at Emory University. Karl Schoene was also tapped as Codexis’ senior vice president of development and operations. Schoene comes to Codexis from Elevance Renewable Sciences, where he served as president, CEO and director.
French biotech DEINOVE has named Alexis Rideau as its CEO. Most recently, Rideau was a strategic partnership manager and team coordinator for BIOASTER.
Emmes has named Joe Sliman chief medical officer. Sliman joins Emmes from Social and Scientific Systems, where he served as senior medical director.
Christine Oliver has been appointed CEO of Endpoint Clinical. Oliver most recently served as chief operating officer of the company.
Rajiv Khosla has been appointed to the role of CEO at Enteris BioPharma. Khosla joins Enteris from CEUTEC, a biopharmaceutical and venture capital consulting firm he founded in 2011.
Galecto has appointed Jonathan Freve to the role of chief financial officer. Freve most recently served as chief financial officer and treasurer of Spring Bank Pharmaceuticals.
Mark Uknis has stepped into the chief medical officer role at Gemini Therapeutics. Uknis leaves a position as Achillion’s vice president and global nephrology development lead.
Goldfinch Bio has appointed Kyle Kuvalanka to the role of chief financial and operating officer. Kuvalanka is a consultant at Third Rock Ventures and was chief operating officer at Syros Pharmaceuticals prior to this appointment. Goldfinch also announced the promotion of Lori Rudolph-Owen from senior vice president of R&D strategy and operations to chief development officer.
Gene therapy company HORAMA appointed Ian Catchpole to the role of chief scientific officer. Catchpole most recently served as director of research at TC BioPharm.
ICON has tapped Kristen Buck, former senior vice president and chief of clinical development at Optum, to join the CRO as its chief medical officer.
Brian Di Donato has been named chief financial officer and head of strategy at Immunocore. Previously, Di Donato was senior vice president and chief financial officer at Achillion Pharmaceuticals.
Impel NeuroPharma has named Adrian Adams, current chairman of the company’s board of directors, as its CEO.
David Lebwohl has been named chief medical officer of Intellia Therapeutics. Lebwohl joins the company after an almost two-year stint as chief medical officer of Semma Therapeutics.
Johnson & Johnson
Johnson and Johnson promoted Najat Khan from the role of chief operating officer to chief data science officer.
Kezar Life Sciences
Noreen Henig has been named chief medical officer of Kezar Life Sciences. Most recently, Henig was chief medical officer of Breath Therapeutics.
LifeMax has appointed Michael Huang to the role of chief medical officer. Huang was recently the chief medical officer of Spruce Biosciences.
Peter Radovich has been named chief operating officer of Mirum Pharmaceuticals. Previously, Radovich was the executive vice president of operations at Global Blood Therapeutics.
Peter Gaccione has joined Myocardial Solutions as its president. Gaccione previously served as executive vice president of North & Central America and president of Elekta.
New Jersey COVID-19 Commission
Merck CEO Ken Frazier has joined the New Jersey COVID-19 Restart and Recovery Commission, which will focus on guiding the state’s post-pandemic recovery strategy, as its chairman.
Malene Brondberg, vice president of investor relations and corporation communications at Nordic Nanovector, has been appointed chief financial officer of the company.
Bob Laughner has been named vice president of regulatory affairs at Orchestra BioMed. Prior to this appointment, Laughner was regulatory director of medical device and combination products for AstraZeneca.
Laurent Lafferrere has been named chief operating officer at PathoQuest. Lafferrere was most recently in charge of the SEQENS Lab R&D Center at SEQENS.
Timothy Jones has been named president and CEO of RespireRx Pharmaceuticals. Jones was most recently the vice president of global pharmaceuticals and medical OTC at Purisys.
Rosana Kapelier will lead Rome Therapeutics as its CEO following the company’s recent acquisition of $50 million in series A capital funding.
Signant Health has appointed Ian Jennings to the role of chief commercial officer. Jennings was most recently an independent consultant for clinical and healthcare technology companies.
Victor Levitsky has assumed the role of chief scientific officer at Targovax. Levitsky was previously vice president and head of oncology research at Molecular Partners.
Tessa Therapeutics has announced the appointment of Jeffrey Buchalter to CEO. Buchalter joined Tessa in 2019 as an independent board director.